• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
Citation: YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116

Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China

More Information
  • In order to provide enlightening experience for the establishment of reasonable and diversified orphan drugs into the reimbursement system in China, the official websites of the National Institute for Health and Care Excellence(NICE)and the National Health Service(NHS)in the UK were inspected, collecting and summarizing the relevant documents, on the inclusion of orphan drugs into the reimbursement system. Relevant literatures were analyzed with theoretical studies on the accessibility of medicines for patients with rare diseases. In the NHS system, the inclusion of orphan drugs into the reimbursement system in the UK can be achieved mainly through seven routes, with three routes that are evaluated by NICE(MTA, STA and HST)and four are directly managed by the NHS(specialized commissioning, CDF, IFRs, CtE). Through the analysis of the inclusion of orphan drugs into the reimbursement system and the various problems in the UK, we have found some enlightening experience for the establishment of the reimbursement system for orphan drugs in China.
  • [1]
    Gong SW.Study of management strategies of improving access to orphan drugs in china(促进我国罕见病患者药品可及性的管理策略研究)[D].Wuhan:Huazhong University of Science and Technology,2008.
    [2]
    Sui BY,Qi XR.Experience from translation mechanisms in the NICE health technology assessment to NHS decision making[J].Chin J Health Policy(中国卫生政策研究),2015,8(7):74-78.
    [3]
    National Institute for Health and Care Excellence.Guide to the processes of technology appraisal2014[R].London:NICE,2014.
    [4]
    National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-03-19] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice technology-appraisal-guidance/summary-of-decisions.
    [5]
    National Institute for Health and Care Excellence.Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease[R].London:NICE,2017.
    [6]
    National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-05-17] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/summary-of-decisions.
    [7]
    National Institute for Health and Care Excellence.Guide to the processes of technology appraisal 2014[R].London:NICE,2014.
    [8]
    National Institute for Health and Care Excellence.Eltrombopag for treating chronic immune(idiopathic)thrombocytopenic purpura[R].London:NICE,2013.
    [9]
    National Institute for Health and Care Excellence.Interim process and methods of the highly specialized technologies programme[R].London:NICE,2017.
    [10]
    National Health Service.Specialized services[EB/OL].[2018-05-18] .https://www.england.nhs.uk/commissioning/spec-services/.
    [11]
    NHS England.Implementation plan for the uk strategy for rare diseases[R].England:NHS England,2018.
    [12]
    NHS England Cancer Drugs Fund Team.Appraisal and funding of cancer drugs from July 2016(including the new Cancer Drugs Fund)- A new deal for patients,taxpayers and industry[R].England:NHS England,2016.
    [13]
    NHS England Cancer Drugs Fund Team.National cancer drugs fund list[R].England:NHS England,2016.
    [14]
    National Institute for Health and Care Excellence.Consultation comments on the draft remit and draft scope for the technology appraisal of cabozantinib for previously treated advanced renal cell carcinoma[R].England:NICE.
    [15]
    Specialized Commissioning Team.Standard operating procedures:individual funding requests[R].England:NHS England,2017.
    [16]
    NHS England.Methods:Commissioning through Evaluation[R].England:NHS England,2017.
    [17]
    National Health Service.Commissioning through evaluation[EB/OL].[2018-05-20] .https://www.england.nhs.uk/commissioning/spec-services/npc-crg/comm-eval/.
  • Related Articles

    [1]CHENG Xiaohong, JIANG Li, DONG Xingting, KANG Xiulin, LIU Lifang. Identification of chemical constituents in Fufang Shechuangzi Xiji(Lotion)by UPLC-Q-TOF-MS/MS[J]. Journal of China Pharmaceutical University, 2022, 53(4): 452-466. DOI: 10.11665/j.issn.1000-5048.20220408
    [2]WANG Jingyi, DONG Yangyang, QI Chulu, ZHANG Jiayao, ZHANG Minjie, WANG Hao. Chemical constituents of the stem bark of Bombax ceiba L.[J]. Journal of China Pharmaceutical University, 2016, 47(5): 570-574. DOI: 10.11665/j.issn.1000-5048.20160511
    [3]XU Yunhui, JIANG Xueyang, XU Jian, JIANG Renwang, ZHANG Jie, XIE Zijian, FENG Feng. Chemical constituents from Callicarpa kwangtungensis Chun[J]. Journal of China Pharmaceutical University, 2016, 47(3): 299-302. DOI: 10.11665/j.issn.1000-5048.20160309
    [4]MA Lin, ZHANG Rongfei, YU Shule, WU Zhengfeng, ZHAO Shouxun, Wang Lei, YE Wencai, ZHANG Jian, YIN Zhiqi. Chemical constituents of Fructus Gleditsiae Abnormalis[J]. Journal of China Pharmaceutical University, 2015, 46(2): 188-193. DOI: 10.11665/j.issn.1000-5048.20150209
    [5]LI Jiu-hui, CHEN Guang-ying, HAN Chang-ri, MO Zheng-rong, SONG Xiao-ping. Chemical constituents from the stems of Vatica mangachpoi Blanco[J]. Journal of China Pharmaceutical University, 2012, 43(1): 25-27.
    [6]QU Wei, ZHAO Ling, LIANG Jing-yu. Chemical constituents from Saururus chinensis(Lour.) Baill[J]. Journal of China Pharmaceutical University, 2011, 42(6): 507-509.
    [7]WANG Hang, FENG Fang, WANG Xue-qua. Chemical constituents of Zhizidahuang decoction detected by HPLC-PDA-ESI-MS/MS[J]. Journal of China Pharmaceutical University, 2009, 40(3): 232-237.
    [8]Chemical Constituents ofDendrobium fimbriatum Hook.([J]. Journal of China Pharmaceutical University, 2001, (3): 42-44.
    [9]Studies of Chemical Constituents of Ficus Carica L[J]. Journal of China Pharmaceutical University, 1996, (4): 13-15.
    [10]COMPARISON BETWEEN THE OIL CONSTITUENTS OF WILD AND OF CULTIVATED A TRACTYLODES LANCEA BY GC/MS[J]. Journal of China Pharmaceutical University, 1989, (5): 289-290.

Catalog

    Article views (844) PDF downloads (1563) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return